A phase 2 trial supports SBRT for primary treatment of localized RCC. Stereotactic body radiotherapy (SBRT) showed favorable long-term local control and cause-specific survival (CSS) in a phase 2 ...
They say a smile is worth a thousand words — but apparently, it can also reveal a little more than that. The latest viral craze on social media claims you can tell a guy’s “endowment” just by his ...
The combination of PD-L1 and CTLA-4 inhibition improves disease-free survival after surgery in patients with primary renal cell carcinoma, a phase 3 trial finds. For patients with renal cell carcinoma ...
Zacks Investment Research on MSN
What's Behind Boston Scientific's Optimism for Urology Growth?
Boston Scientific BSX delivered solid sales in the Urology franchise in the third quarter of 2025, growing 27% operationally and 5% organically. The business specializes in devices to treat various ...
Fox Chase Cancer Center announced the hiring of Mary Novak, DO, as an Assistant Professor in the Department of Urology and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback